Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 6/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17759085 | 0.79 | ELANE (0.41) | CLK1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL17754847 | 0.76 | IRAK4 (0.42) | IRAK4PRMT5WDR77FYNCLK1 | |
| SCHEMBL17759101 | 0.75 | MAP3K14 (0.43) | CLK1DYRK1A | |
| SCHEMBL19962292 | 0.75 | IRAK4 (0.41) | IRAK4PRMT5WDR77FYNCLK1 | |
| SCHEMBL9941690 | 0.73 | CLK1 (0.48) | CLK1DYRK1ATGFBR1 | |
| SCHEMBL23108642 | 0.72 | MET (0.42) | IRAK4PRMT5WDR77PKMFYN | |
| SCHEMBL23133611 | 0.72 | IRAK4 (0.40) | IRAK4PRMT5WDR77FYNCLK1 | |
| SCHEMBL17697727 | 0.72 | RIPK2 (0.38) | IRAK4PRMT5WDR77PKMFYN | |
| SCHEMBL22045717 | 0.71 | EIF2AK4 (0.39) | SMN1; SMN2KDM4EDYRK1AALDH1A1 | |
| Bromide SCHEMBL31538783 | 0.71 | IRAK4 (0.39) | IRAK4PRMT5WDR77FYNCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012259-B1 | FIVE-MEMBERED HETEROCYCLIC PYRIDINE COMPOUNDS AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-06-03 | — | — | EP | disclosed |
| US-9988381-B2 | Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20160137640-A1 | FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO. LTD. (CN) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137640-A1 | FIVE-MEMBER-HETEROCYCLE FUSED PYRIDINE COMPOUNDS, METHOD OF PRODUCING THE SAME, AND USE THEREOF | ABL1, JAK2, LCK | IRAK4 288/4885PRMT5 644/4885WDR77 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.